BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2864788)

  • 21. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetic of haloperidol decanoate in psychotic patients (author's transl)].
    Parent M; Toussaint C; Driesens F; Gelders Y
    Acta Psychiatr Belg; 1981; 81(4):399-406. PubMed ID: 7331843
    [No Abstract]   [Full Text] [Related]  

  • 23. [Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
    Balant-Gorgia AE; Eisele R; Garrone G
    Schweiz Med Wochenschr; 1985 Jan; 115(1):14-8. PubMed ID: 2857499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
    Gelders YG
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
    Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
    J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haloperidol decanoate (Janssen) in the treatment of sexual deviations.
    Zbytovský J
    Cesk Psychiatr; 1993 Jan; 89(1):15-7. PubMed ID: 8099535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug treatment of schizophrenic psychoses in puerperium].
    Olbrich HM; Martin P
    Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses].
    Cesková E; Svestka J; Rysánek R
    Cesk Psychiatr; 1993 Jan; 89(1):11-4. PubMed ID: 8099534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flupenthixol versus haloperidol in acute psychosis.
    Parent M; Toussaint C
    Pharmatherapeutica; 1983; 3(5):354-64. PubMed ID: 6844372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depot neuroleptics for acutely psychotic patients.
    Turns DM; Pary R; Tobias CR; James WA
    Am J Psychiatry; 1987 Aug; 144(8):1099-100. PubMed ID: 2886066
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacology and mechanism of action of existing and new neuroleptics.
    Niemegeers CJ
    Acta Psiquiatr Psicol Am Lat; 1990; 36(1-2):26-36. PubMed ID: 1981439
    [No Abstract]   [Full Text] [Related]  

  • 37. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
    Deberdt R; Elens P; Berghmans W; Heykants J; Woestenborghs R; Driesens F; Reyntjens A; van Wijngaarden I
    Acta Psychiatr Scand; 1980 Oct; 62(4):356-63. PubMed ID: 7468294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 12-month study of haloperidol decanoate in chronic schizophrenic patients.
    Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A six-month follow-up of refractory chronic psychotics treated with Haldol-AID.
    Wouters J
    Acta Psychiatr Belg; 1978; 78(2):399-406. PubMed ID: 354327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [7 years of experience with delayed action neuroleptics].
    Noguera Hosta R; Rendueles de Olmedo G
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1978; 6(3):293-8. PubMed ID: 31066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.